Insmed Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious and rare diseases. The company specializes in creating treatments for conditions related to severe respiratory infections, particularly those caused by non-tuberculous mycobacteria. Insmed’s research and development efforts are driven by a commitment to address unmet medical needs, utilizing advanced science and technology to bring forward new options for patients who often have limited alternatives. Through their clinical programs, Insmed aims to improve health outcomes and enhance the quality of life for individuals suffering from these challenging conditions. Read More
Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial.
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Indications Suggest NASDAQ:INSM Could Be on the Verge of a Breakout. Here's What You Need to Know.
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.
